Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by Analysts at Robert W. Baird

Equities research analysts at Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage set an “outperform” rating and a $57.00 price target on the stock. Robert W. Baird’s price objective indicates a potential upside of 131.05% from the company’s previous close.

Other research analysts have also issued reports about the company. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating for the company. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Finally, HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a report on Monday. They issued a “buy” rating and a $60.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Sensei Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $58.50.

Sensei Biotherapeutics Price Performance

Shares of FTH opened at $24.67 on Friday. Sensei Biotherapeutics has a 12 month low of $6.32 and a 12 month high of $36.76.

Insider Buying and Selling at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, CEO Anand Kiran Parikh bought 2,806 shares of the stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the purchase, the chief executive officer owned 764,234 shares in the company, valued at $15,101,263.84. This represents a 0.37% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brian C. Stephenson acquired 9,230 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were bought at an average cost of $24.36 per share, for a total transaction of $224,842.80. Following the acquisition, the chief financial officer owned 17,413 shares in the company, valued at approximately $424,180.68. The trade was a 112.79% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 20,219 shares of company stock worth $461,379 in the last 90 days. Company insiders own 7.00% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.